Millennium Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.9M | Buy |
377,178
+346,686
| +1,137% | +$18.3M | 0.01% | 1644 |
|
|
2025
Q4 | $1.6M | Sell |
30,492
-55,790
| -65% | -$3.34M | ﹤0.01% | 4128 |
|
|
2025
Q3 | $5.59M | Buy |
86,282
+16,189
| +23% | +$929K | ﹤0.01% | 3026 |
|
|
2025
Q2 | $3.41M | Sell |
70,093
-513,640
| -88% | -$19.9M | ﹤0.01% | 3372 |
|
|
2025
Q1 | $19.9M | Buy |
583,733
+575,235
| +6,769% | +$24.4M | 0.01% | 1525 |
|
|
2024
Q4 | $334K | Sell |
8,498
-101,587
| -92% | -$4.8M | ﹤0.01% | 5012 |
|
|
2024
Q3 | $5.17M | Buy |
110,085
+83,759
| +318% | +$4.25M | ﹤0.01% | 2810 |
|
|
2024
Q2 | $1.42M | Sell |
26,326
-79,317
| -75% | -$4.59M | ﹤0.01% | 3819 |
|
|
2024
Q1 | $7.2M | Buy |
105,643
+88,373
| +512% | +$6.33M | ﹤0.01% | 2499 |
|
|
2023
Q4 | $1.08M | Sell |
17,270
-118,960
| -87% | -$6.58M | ﹤0.01% | 4094 |
|
|
2023
Q3 | $6.18M | Buy |
136,230
+73,983
| +119% | +$3.82M | ﹤0.01% | 2504 |
|
|
2023
Q2 | $3.49M | Sell |
62,247
-167,730
| -73% | -$9.52M | ﹤0.01% | 2987 |
|
|
2023
Q1 | $10.4M | Buy |
229,977
+217,833
| +1,794% | +$10.6M | 0.01% | 1928 |
|
|
2022
Q4 | $494K | Buy |
12,144
+2,533
| +26% | +$134K | ﹤0.01% | 4753 |
|
|
2022
Q3 | $628K | Buy |
+9,611
| New | +$697K | ﹤0.01% | 4753 |
|
|
2022
Q2 | – | Sell |
-45,788
| Closed | -$2.69M | – | 7043 |
|
|
2022
Q1 | $2.87M | Sell |
45,788
-340,078
| -88% | -$21.4M | ﹤0.01% | 3537 |
|
|
2021
Q4 | $29.2M | Buy |
385,866
+194,166
| +101% | +$17M | 0.01% | 1108 |
|
|
2021
Q3 | $21.5M | Buy |
191,700
+99,061
| +107% | +$12.4M | 0.01% | 1261 |
|
|
2021
Q2 | $15M | Sell |
92,639
-10,473
| -10% | -$1.27M | 0.01% | 1473 |
|
|
2021
Q1 | $12.6M | Buy |
103,112
+80,927
| +365% | +$12.2M | 0.01% | 1540 |
|
|
2020
Q4 | $3.4M | Buy |
+22,185
| New | +$2.62M | ﹤0.01% | 2801 |
|
|
2020
Q3 | – | Sell |
-20,592
| Closed | -$1.51M | – | 4504 |
|
|
2020
Q2 | $1.51M | Buy |
+20,592
| New | +$1.2M | ﹤0.01% | 2729 |
|
|
2020
Q1 | – | Sell |
-312,433
| Closed | -$19M | – | 3943 |
|
|
2019
Q4 | $19M | Buy |
312,433
+205,895
| +193% | +$11.2M | 0.02% | 880 |
|
|
2019
Q3 | $4.37M | Buy |
+106,538
| New | +$5.09M | 0.01% | 1918 |
|
|
2018
Q4 | – | Sell |
-67,179
| Closed | -$2.98M | – | 3807 |
|
|
2018
Q3 | $2.98M | Buy |
+67,179
| New | +$3.52M | ﹤0.01% | 2146 |
|
|
2018
Q1 | – | Sell |
-95,130
| Closed | -$2.23M | – | 3701 |
|
|
2017
Q4 | $2.23M | Buy |
95,130
+19,858
| +26% | +$377K | ﹤0.01% | 2213 |
|
|
2017
Q3 | $1.34M | Buy |
75,272
+42,272
| +128% | +$767K | ﹤0.01% | 2367 |
|
|
2017
Q2 | $529K | Buy |
+33,000
| New | +$545K | ﹤0.01% | 2772 |
|
|
2017
Q1 | – | Sell |
-11,913
| Closed | -$241K | – | 3536 |
|
|
2016
Q4 | $241K | Buy |
+11,913
| New | +$223K | ﹤0.01% | 3006 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Millennium Management's CRSP Position: Q1 2026 in Review
Millennium Management increased its CRISPR Therapeutics (CRSP) stake by 1,137% in Q1 2026, buying an estimated $18.3M and bringing the position to 377,178 shares worth $17.9M. The position accounts for 0.01% of the portfolio, ranked #1644.
Millennium Management first reported a position in CRSP in Q4 2016 and has held it in 29 quarters since. The position peaked at $29.2M in Q4 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Millennium Management held 377,178 shares of CRISPR Therapeutics worth $17.9M as of Q1 2026.
- Millennium Management bought 346,686 CRISPR Therapeutics shares in Q1 2026, an estimated $18.3M.
- CRISPR Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1644 holding.
- Millennium Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 29 quarters since.
- Millennium Management's CRISPR Therapeutics position peaked at $29.2M in Q4 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.